Oxidant/antioxidant status in premenstrual syndrome

Duvan, Candan İltemir; Cumaoğlu, Ahmet; Turhan, Nilgün Öztürk; Karasu, Çi̇men; Kafalı, Hasan

doi:10.1007/s00404-009-1347-y

Cited by 45 publications

(57 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a preliminary study, subjects with PMS showed no evidence of oxidative damage [48]. In two studies that used malondialdehyde (MDA) as a marker of oxidative stress, no difference was observed between PMS patients and controls [5,49]. Conversely, a study by Duvan et al [5] reported a significant difference in LPH levels between controls and patients with PMS, and they found that TAC was significantly decreased in the PMS group.…”

Section: Role Of Oxidative Stress and Pon-1 In Pmddmentioning

confidence: 97%

“…In two studies that used malondialdehyde (MDA) as a marker of oxidative stress, no difference was observed between PMS patients and controls [5,49]. Conversely, a study by Duvan et al [5] reported a significant difference in LPH levels between controls and patients with PMS, and they found that TAC was significantly decreased in the PMS group. Importantly, the authors did not evaluate well-known confounding factors such as depression, anxiety, and sleep quality.…”

Section: Role Of Oxidative Stress and Pon-1 In Pmddmentioning

confidence: 99%

“…PMDD, which was first defined as a severe form of PMS in the fourth text revision of the DSM-IV TR, was listed as a depressive disorder in the DSM-5, and a diagnosis requires the prospective assessment of two consecutive menstrual periods [4][5][6]. PMDD is a cyclic pattern of symptoms that begins during the late luteal phase of the menstrual cycle and subsides shortly after the onset of menstruation; it is diagnosed by the existence of at least one affective symptom (depressed mood, anxiety, affective lability, marked anger, or irritability) and five or more total symptoms including affective symptoms [4,5]. Numerous biological factors have been proposed to influence PMDD pathogenesis, including progesterone deficiency, serotonergic dysfunction, and disturbed endorphin modulation by gonadal steroids and their products [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…Measuring the total antioxidant capacity (TAC) requires the simultaneous quantification of several antioxidant markers and is one indicator of oxidative status [5]. Oxidative stress may lead to premature cell death and is associated with many ischemic and inflammatory diseases, degenerative disorders, and psychiatric disorders such as depression, bipolar disorder, schizophrenia, obsessive compulsive disorder, sleep disorders, and anxiety disorders [18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

“…The inflammatory processes that may trigger tissue desquamation at menstruation remain to be clarified, but some studies have shown alterations in inflammation markers in relation to menstrual [30] and premenstrual symptom severity [31]. A recent study described increased lipid hydroperoxide, which is commonly used to assess oxidative levels, and decreased TAC in subjects with PMS in their luteal phases [5]. Another group reported that subjects with PMS had total oxidant status (TOS) levels non-significantly higher that and TAC levels similar with those of controls [32].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: a follow-up study

Özcan

Oral

Güleç

et al. 2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Objective: Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) that was categorized as a mood disorder in the most recent version of the Diagnostic and Statistical Manual for Mental Disorders. In addition to a history of PMS, a PMDD diagnosis requires prospective symptom assessment for 2 consecutive menstrual periods. Although the effects of some oxidants-antioxidants were previously studied in PMS, their possible effects in PMDD remain unknown. Paraoxonase-1 (PON-1) is a new high-density lipoproteinassociated enzyme with many antioxidative effects. We hypothesized that assessing serum total oxidant-antioxidant and PON-1 levels could clarify the role of oxidant-antioxidant system in PMDD. Methods: All participants (n = 50) were assessed by an experienced psychiatrist for PMDD by using the Diagnostic and Statistical Manual for Mental Disorders-IV (DSM-IV), Premenstrual Assessment Form and Daily Record of Severity of Problems (DRSP)-Short Form or possible psychiatric disorders including depression, anxiety, and sleep disorders. Serum estrogen, progesterone, total oxidant-antioxidant, and paraoxonase-1 (PON-1) levels were measured in the serum of 20 participants with PMDD and 30 asymptomatic controls during the follicular and luteal phases of two consecutive menstrual cycles. Sleep quality, depression, and anxiety symptoms were assessed with the Pittsburg Sleep Quality Index (PSQI), Hamilton Depression Rating Scale (HDRS), and Hamilton Anxiety Rating Scale (HARS), respectively. Results: There were no significant intergroup differences in estrogen, progesterone, oxidantantioxidant, or PON-1 levels or PSQI scores. However, the mean HDRS and HARS scores were statistically significantly higher for patients with PMDD than for controls. Levels of estrogen, progesterone, and total oxidant-antioxidant were not correlated with HDRS, HARS, or PSQI scores. Conclusions: Considering the lack of differences in hormonal and biochemical levels between the two groups, it may be more efficient and discriminative to longitudinally assess biochemical and cellular stress-related parameters in subjects with PMDD. ARTICLE HISTORY

show abstract

Section: Role Of Oxidative Stress and Pon-1 In Pmddmentioning

confidence: 97%

Section: Role Of Oxidative Stress and Pon-1 In Pmddmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: a follow-up study

Özcan

Oral

Güleç

et al. 2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

Antioxidants in Reproductive Health and Fertility

Darché

Ruder

Blumberg

et al. 2017

Nutritional Antioxidant Therapies: Treatments and Perspectives

View full text Add to dashboard Cite

Gynecological Management of Premenstrual Symptoms

Shulman

2010

Curr Pain Headache Rep

View full text Add to dashboard Cite

The vast majority of menstruating women experience uncomfortable symptoms during the premenstrual phase of their menstrual cycles. Although many women do not require specific treatment of their symptoms, approximately 20% to 50% report moderate to severe premenstrual symptoms and about 5% meet the diagnostic criteria for premenstrual dysphoric disorder, the most severe manifestation of premenstrual symptoms. While the etiology of premenstrual symptoms remains unclear, several theories have implicated sex steroids and neurotransmitters in the development and manifestation of symptoms. Further complicating the delineation of etiology is that premenstrual symptoms can be somatic, psychological, or behavioral, as well as a combination of all three. Developing successful interventions for premenstrual symptoms has thus been challenging, with interventions focused on a particular aspect of premenstrual symptomatology. Treatments for premenstrual symptoms include lifestyle changes, cognitive behavioral therapies, and pharmacologic agents including ovulation suppression regimens, antidepressant medications, and anxiolytics.

show abstract

Oxidant/antioxidant status in premenstrual syndrome

Abstract: Increased oxidative stress and reduced antioxidant capacity may occur in PMS. It can be speculated that the imbalance of oxidant/antioxidant systems may be a cause or the consequence of the various stress symptoms in PMS.

Cited by 45 publications

References 26 publications

Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: a follow-up study

Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: a follow-up study

Antioxidants in Reproductive Health and Fertility

Gynecological Management of Premenstrual Symptoms

Contact Info

Product

Resources

About